- Home
- RXO vs VCYT Comparison
RXO vs VCYT Comparison
Compare RXO & VCYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RXO | VCYT |
|---|---|---|
| Founded | 2022 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.6B |
| IPO Year | 2022 | 2013 |
Fundamental Metrics
Financial Performance| Metric | RXO | VCYT |
|---|---|---|
| Price | $18.17 | $32.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | $16.33 | ★ $44.00 |
| AVG Volume (30 Days) | ★ 1.7M | 551.5K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 72.81 | ★ 164.52 |
| EPS | N/A | ★ 0.82 |
| Revenue | ★ $5,742,000,000.00 | N/A |
| Revenue This Year | $0.49 | $13.76 |
| Revenue Next Year | $6.90 | $12.35 |
| P/E Ratio | ★ N/A | $41.10 |
| Revenue Growth | ★ 26.20 | N/A |
| 52 Week Low | $10.43 | $22.61 |
| 52 Week High | $20.38 | $50.71 |
Technical Indicators
Market Signals| Indicator | RXO | VCYT |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 48.26 |
| Support Level | $16.17 | $31.00 |
| Resistance Level | $18.69 | $34.37 |
| Average True Range (ATR) | 0.96 | 1.38 |
| MACD | -0.18 | 0.01 |
| Stochastic Oscillator | 42.27 | 46.43 |
Price Performance
Historical ComparisonAbout RXO RXO Inc.
RXO Inc is a brokered transportation platform defined by cutting-edge technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.
About VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).